Guidelines

• NCCN Guidelines Version 6.2022

Evidence Blocks

• NCCN Guidelines with Evidence Blocks Version 5.2022

Frameworks

• Basic Resources (English) Version 3.2022

• Core Resources (English) Version 3.2022

• Enhanced Resources (English) Version 3.2022

Guidelines for Patients

• Non-Small Cell Lung Cancer - Early and Locally Advanced-English Version 2022

• Non-Small Cell Lung Cancer - Metastatic-English Version 2022

• Non-Small Cell Lung Cancer - Metastatic-Korean Version 2021

• Non-Small Cell Lung Cancer - Early and Locally Advanced-Russian Version 2019

• Non-Small Cell Lung Cancer - Metastatic-Russian Version 2019

• Non-Small Cell Lung Cancer - Early and Locally Advanced-Ukrainian Version 2021

• Non-Small Cell Lung Cancer - Metastatic-Ukrainian Version 2021

Educational Events and Programs

Calendar of Events

Continuing Education

• NCCN Guidelines® Insights - Lung Cancer Screening, Version 1.2022

• Clinical Scenario #1: Applying Biomarkers in Metastatic Non-Small Cell Lung Cancer

• Archived Monthly Oncology Tumor Boards: New Targeted Therapies for Non-Small Cell Lung Cancer

• Non-Small Cell Lung Cancer: Management of Patients with Resectable Disease

• Challenging Case Review: Non-Small Cell Lung Cancer

• NCCN Pharmacy Updates: Updates in Biomarker-Driven Therapy in Non-Small Cell Lung Cancer

• Recorded Presentation from the NCCN Pharmacy Updates: Updates in Biomarker-Driven Therapy in Non-Small Cell Lung Cancer

International

Disclosures

• Disclosure Policy

• Panel Member Disclosures

• Panel Member Disclosures by Meeting Date

• End User License Agreement